Cited by 101Viral-associated cancers and disordersCervical Cancer and HPV ResearchHepatitis B Virus Studies

The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.

Vaccines to Prevent Infections by Oncoviruses

Open access

Schiller, John T., Lowy, Douglas R.·2010·Annual Review of Microbiology

DOI 10.1146/annurev.micro.112408.134019PMC PMC6264788

Open this paper in CoChat — free account

Abstract

It has been estimated that viruses are etiological agents in approximately 12% of human cancers. Most of these cancers can be attributed to infections by human papillomavirus (HPV), hepatitis B virus (HBV), hepatitis C virus (HCV), Epstein-Barr virus (EBV), and Kaposi's sarcoma–associated herpesvirus (KSHV). Prophylactic vaccines against other pathogenic viruses have an excellent record as public health interventions in terms of safety, effectiveness, and ability to reach economically disadvantaged populations. These considerations should prompt efforts to develop and implement vaccines against oncoviruses. Safe and effective HBV and HPV vaccines, based on virus-like particles, are commercially available, and the major focus is now on vaccine delivery, especially to low-resource settings. HCV and EBV vaccines are under active development, but few clinical trials have been conducted, and none of the candidate vaccines has proven to be sufficiently effective to warrant commercialization. Efforts to develop KSHV vaccines have been more limited.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1146/annurev.micro.112408.134019

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

Identification of a Novel Gammaretrovirus in Prostate Tumors of Patients Homozygous for R462Q RNASEL Variant
Urisman, A., Molinaro, R. J., Fischer, N., Plummer, S. J., Casey, G., Klein, E. A., Malathi, K., Magi-Galluzzi, C., Tubbs, R. R., Ganem, D., et al. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020025 · Cited by 577
Retracted
Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's Sarcoma
Chang, Y., Cesarman, E., Pessin, M. S., Lee, F., Culpepper, J., Knowles, D. M., & Moore, P. S. (1994) · Science · doi:10.1126/science.7997879 · Cited by 5,608
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma
Poiesz, B. J., Ruscetti, F. W., Gazdar, A. F., Bunn, P. A., Minna, J. D., & Gallo, R. C. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.12.7415 · Cited by 5,043 · cited 1×
“Human T cell leukemia virus type 1 (HTLV1) was first identified in 1980 from a patient with cutaneous T cell leukemia (66).”
Background
The causal relation between human papillomavirus and cervical cancer
Bosch, F. X., Lorincz, A. T., Munoz, N., Meijer, C. J. L. M., & Shah, K. V. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.4.244 · Cited by 3,587
Clonal Integration of a Polyomavirus in Human Merkel Cell Carcinoma
Feng, H., Shuda, M., Chang, Y., & Moore, P. S. (2008) · Science · doi:10.1126/science.1152586 · Cited by 3,208
The global health burden of infection‐associated cancers in the year 2002
Parkin, D. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21731 · Cited by 2,932
HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS
Beasley, R. P., Lin, C., Hwang, L., & Chien, C. (1981) · The Lancet · doi:10.1016/s0140-6736(81)90585-7 · Cited by 2,856
VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA
Epstein, M. A., Achong, B. G., & Barr, Y. M. (1964) · The Lancet · doi:10.1016/s0140-6736(64)91524-7 · Cited by 2,793
Global epidemiology of hepatitis C virus infection
Shepard, C. W., Finelli, L., & Alter, M. J. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70216-4 · Cited by 2,758
Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera.
Hinuma, Y., Nagata, K., Hanaoka, M., Nakai, M., Matsumoto, T., Kinoshita, K. I., Shirakawa, S., & Miyoshi, I. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.10.6476 · Cited by 2,252
A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions.
Dürst, M., Gissmann, L., Ikenberg, H., & Hausen, H. Z. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.12.3812 · Cited by 2,025
Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in Children
Chang, M.-H., Chen, C.-J., Lai, M.-S., Hsu, H.-M., Wu, T.-C., Kong, M.-S., Liang, D.-C., Shau, W.-Y., & Chen, D.-S. (1997) · New England Journal of Medicine · doi:10.1056/nejm199706263362602 · Cited by 1,883
A Controlled Trial of a Human Papillomavirus Type 16 Vaccine
Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., Chiacchierini, L. M., & Jansen, K. U. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020586 · Cited by 1,719
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women
Paavonen, J., Naud, P., Salmerón, J., Wheeler, C., Chow, S.-N., Apter, D., Kitchener, H., Castellsague, X., Teixeira, J., Skinner, Sr., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61248-4 · Cited by 1,655
Hepatitis B Virus Immunopathogenesis
Chisari, F. V., & Ferrari, C. I. (1995) · Annual Review of Immunology · doi:10.1146/annurev.iy.13.040195.000333 · Cited by 1,584
Epidemiology of Hepatocellular Carcinoma
Bosch, F. X., Ribes, J., Clèries, R., & Díaz, M. (2005) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.12.009 · Cited by 1,130
Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes
Bartosch, B., Dubuisson, J., & Cosset, F. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021756 · Cited by 1,111
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.
Kirnbauer, R., Booy, F. P., Cheng, N., Lowy, D. R., & Schiller, J. T. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12180 · Cited by 1,107
Self-citation
Hepatitis B: The virus and disease #
Liang, J. T. (2009) · Hepatology · doi:10.1002/hep.22881 · Cited by 1,066
The epidemiology of human papillomavirus infections
Baseman, J. G., & Koutsky, L. A. (2005) · Journal of Clinical Virology · doi:10.1016/j.jcv.2004.12.008 · Cited by 957
Epidemiology and Natural History of Human Papillomavirus Infections and Type-Specific Implications in Cervical Neoplasia
Bosch, F. X., Burchell, A. N., SCHIFFMAN, M. H., Giuliano, A. R., de Sanjosé, S., Bruni, L., Tortolero‐Luna, G., Kjær, S. K., & Muñóz, N. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.05.064 · Cited by 841
Cancer risk in people infected with human immunodeficiency virus in the United States
Engels, E. A., Biggar, R. J., Hall, H. I., Cross, H., Crutchfield, A., Finch, J. L., Grigg, R., Hylton, T., Pawlish, K. S., McNeel, T. S., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23487 · Cited by 756
A mathematical model to estimate global hepatitis B disease burden and vaccination impact.
Goldstein, S. T., Zhou, F., Hadler, S. C., Bell, B. P., Mast, E. E., & Margolis, H. S. (2005) · International Journal of Epidemiology · doi:10.1093/ije/dyi206 · Cited by 743
Human hepatitis B vaccine from recombinant yeast
McAleer, W. J., Buynak, E. B., Maigetter, R. Z., Wampler, D. E., Miller, W. J. W., & Hilleman, M. R. (1984) · Nature · doi:10.1038/307178a0 · Cited by 740
Transfusion-Associated Hepatitis Not Due to Viral Hepatitis Type A or B
Feinstone, S. M., Kapikian, A. Z., Purcell, R. H., Alter, H. J., & Holland, P. V. (1975) · New England Journal of Medicine · doi:10.1056/nejm197504102921502 · Cited by 687
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus‐Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV‐Naive Women Aged 16–26 Years
Brown, D. R., Kjær, S. K., Sigurðsson, K., Iversen, O., Hernández‐Ávila, M., Wheeler, C. M., Pérez, G., Koutsky, L. A., Tay, E. H., Garcia, P. J., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/597307 · Cited by 638
Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study
Chang, M., You, S., Chen, C., Liu, C., Lee, C., Lin, S., Chu, H.-C., Wu, T., Yang, S., Kuo, H., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp288 · Cited by 633
Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon
Kato, T., Date, T., Miyamoto, M., Furusaka, A., Tokushige, K., Mizokami, M., & Wakita, T. (2003) · Gastroenterology · doi:10.1053/j.gastro.2003.09.023 · Cited by 589
Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C
Pestka, J. M., Zeisel, M. B., Bläser, E., Schürmann, P., Bartosch, B., Cosset, F., Patel, A. H., Meisel, H., Baumert, J. J., Viazov, S. O., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607026104 · Cited by 565
HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women
Gillison, M. L., Chaturvedi, A. K., & Lowy, D. R. (2008) · Cancer · doi:10.1002/cncr.23764 · Cited by 530
Self-citation
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan
Roberts, J. N., Buck, C. B., Thompson, C. D., Kines, R. C., Bernardo, M., Choyke, P. L., Lowy, D. R., & Schiller, J. T. (2007) · Nature Medicine · doi:10.1038/nm1598 · Cited by 504
Self-citation
SPECTRUM OF EPSTEIN-BARR VIRUS–ASSOCIATED DISEASES
Kutok, J. L., & Wang, F. (2006) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100209 · Cited by 494
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?
Stamatatos, L., Morris, L., Burton, D. R., & Mascola, J. R. (2009) · Nature Medicine · doi:10.1038/nm.1949 · Cited by 430
The influence of age on the development of the hepatitis B carrier state
Edmunds, W. J., Medley, G. F., Nokes, D. J., Hall, A. J., & Whittle, H. (1993) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.1993.0102 · Cited by 425
Recombinant gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epstein‐Barr Virus Vaccine in Healthy Young Adults
Sokal, E. M., Hoppenbrouwers, K., Vandermeulen, C., Moutschen, M. P., Léonard, P., Moreels, A., Haumont, M., Bollen, A., Smets, F. N., & Denis, M. (2007) · The Journal of Infectious Diseases · doi:10.1086/523813 · Cited by 425
The global impact of vaccination against hepatitis B: A historical overview
Zanetti, A. R., Damme, P. V., & Shouval, D. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.056 · Cited by 422
Kaposi's Sarcoma-Associated Herpesvirus
Boshoff, C., & Weiss, R. A. (1998) · Advances in cancer research · doi:10.1016/s0065-230x(08)60739-3 · Cited by 398
A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions
Kjær, S. K., Sigurðsson, K., Iversen, O., Hernández‐Ávila, M., Wheeler, C. M., Pérez, G., Brown, D. R., Koutsky, L. A., Tay, E. H., Garcia, P. J., et al. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0031 · Cited by 338
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results
Schiller, J. T., Castellsagué, X., Villa, L. L., & Hildesheim, A. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.06.002 · Cited by 334
Self-citation
Hepatitis B Vaccines
Pattyn, J., Hendrickx, G., Vorsters, A., & Damme, P. V. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa668 · Cited by 328
Flying Under the Radar: The Immunobiology of Hepatitis C
Dustin, L. B., & Rice, C. M. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141602 · Cited by 313
Prospects for a vaccine against the hepatitis C virus
Houghton, M., & Abrignani, S. (2005) · Nature · doi:10.1038/nature04081 · Cited by 312
The 4th nation‐wide study of adult T‐cell leukemia/lymphoma (ATL) in Japan: Estimates of risk of ATL and its geographical and clinical features
Tajima, K., The T‐ and B‐Cell Malignancy Study Group, & Co‐Authors (1990) · International Journal of Cancer · doi:10.1002/ijc.2910450206 · Cited by 310
KSHV INFECTION AND THE PATHOGENESIS OF KAPOSI'S SARCOMA
Ganem, D. (2006) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100133 · Cited by 299
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components
Strowig, T., Gurer, C., Ploß, A., Liu, Y., Arrey, F., Sashihara, J., Koo, G. C., Rice, C. M., Young, J. W., Chadburn, A., et al. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20081720 · Cited by 296
The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding
Kines, R. C., Thompson, C. D., Lowy, D. R., Schiller, J. T., & Day, P. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908502106 · Cited by 292
Self-citation
Hepatitis B virus-induced oncogenesis
Lupberger, J. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i1.74 · Cited by 266
Treatment of solid organ transplant recipients with autologous Epstein Barr virus–specific cytotoxic T lymphocytes (CTLs)
Savoldo, B., Goss, J. A., Hammer, M. M., Zhang, L., Lopez, T., Gee, A. P., Lin, Y., Quirós‐Tejeira, R. E., Reinke, P., Schubert, S., et al. (2006) · Blood · doi:10.1182/blood-2006-05-021782 · Cited by 264
Early Experience with Human Papillomavirus Vaccine Introduction in the United States, Canada and Australia
Shefer, A. M., Markowitz, L. E., Deeks, S. L., Tam, T. W. S., Irwin, K. L., Garland, S. M., & Schuchat, A. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.05.065 · Cited by 217
HIV/AIDS: Epidemiology, Pathophysiology, and Treatment of Kaposi Sarcoma–Associated Herpesvirus Disease: Kaposi Sarcoma, Primary Effusion Lymphoma, and Multicentric Castleman Disease
Sullivan, R. J., Pantanowitz, L., Casper, C., Stebbing, J., & Dezube, B. J. (2008) · Clinical Infectious Diseases · doi:10.1086/592298 · Cited by 174
Hepatitis B virus variants
Chotiyaputta, W., & Lok, A. S.-F. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.107 · Cited by 169
Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines
Jagu, S., Karanam, B., Gambhira, R., Chivukula, S. V., Chaganti, R. J., Lowy, D. R., Schiller, J. T., & Roden, R. B. S. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp106 · Cited by 165
Self-citation
Human papillomavirus infection and the primary and secondary prevention of cervical cancer
Lowy, D. R., Solomon, D., Hildesheim, A., Schiller, J. T., & Schiffman, M. (2008) · Cancer · doi:10.1002/cncr.23704 · Cited by 160
Self-citation
Epstein–Barr virus infection in humans: from harmless to life endangering virus–lymphocyte interactions
Klein, E., Kis, L. L., & Klein, G. (2007) · Oncogene · doi:10.1038/sj.onc.1210240 · Cited by 155
Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses☆
David, M., Herck, K. V., Hardt, K., Tibaldi, F. S., Dubin, G. O., Descamps, D., & Damme, P. V. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.01.011 · Cited by 152
Phase I Trial of a CD8+T-Cell Peptide Epitope-Based Vaccine for Infectious Mononucleosis
Elliott, S. L., Suhrbier, A., Miles, J. J., Lawrence, G., Pye, S. J., Le, T. T., Rosenstengel, A., Nguyen, T. H., Allworth, A. M., Burrows, S. R., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01409-07 · Cited by 146
Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity
Zhang, P. C., Zhong, L., Struble, E. B., Watanabe, H., Kachko, A. V., Mihalik, K., Virata, M. L., Alter, H. J., Feinstone, S. M., & Major, M. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902749106 · Cited by 145
Cellular and molecular biology of HCV infection and hepatitis
Tang, H., & Grisé, H. (2009) · Clinical Science · doi:10.1042/cs20080631 · Cited by 134
Angiogenic Effects of Extracellular Human Immunodeficiency Virus Type 1 Tat Protein and Its Role in the Pathogenesis of AIDS-Associated Kaposi's Sarcoma
Barillari, G., & Ensoli, B. (2002) · Clinical Microbiology Reviews · doi:10.1128/cmr.15.2.310-326.2002 · Cited by 119
Immunogenicity Testing in Human Papillomavirus Virus‐Like‐Particle Vaccine Trials
Schiller, J. T., & Lowy, D. R. (2009) · The Journal of Infectious Diseases · doi:10.1086/599988 · Cited by 117
Self-citation
Vaccine strategies against Epstein‐Barr virus‐associated diseases: lessons from studies on cytotoxic T‐cell‐mediated immune regulation
Khanna, R., Moss, D. J., & Burrows, S. R. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01328.x · Cited by 112
Immune escape by Epstein Barr virus associated malignancies
Münz, C., & Moormann, A. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.10.002 · Cited by 110
Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand
Poovorawan, Y., Chongsrisawat, V., Theamboonlers, A., Bock, H. L., Leyssen, M., & Jacquet, J. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.10.074 · Cited by 104
Primary Prevention of HTLV-I in Japan
Hino, S., Katamine, S., Miyata, H., Tsuji, Y., Yamabe, T., & Miyamoto, T. (1996) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/00042560-199600001-00030 · Cited by 103
Transmission of human herpesvirus 8: an update
Pica, F., & Volpi, A. (2007) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3280143919 · Cited by 99
Development of hepatitis C virus vaccines: challenges and progress
Stoll‐Keller, F., Barth, H., Fafi‐Kremer, S., Zeisel, M. B., & Baumert, T. F. (2009) · Expert Review of Vaccines · doi:10.1586/14760584.8.3.333 · Cited by 96
Human T Cell Lymphotropic Virus (HTLV) Type–1–Specific CD8+T Cells: Frequency and Immunodominance Hierarchy
Goon, P. K. C., Biancardi, A., Fast, N. M., Igakura, T., Hanon, E., Mosley, A. J., Asquith, B., Gould, K. G., Marshall, S. E., Taylor, G. P., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/420832 · Cited by 88
Modulation of the immune system by Kaposi's sarcoma-associated herpesvirus
Aresté, C., & Blackbourn, D. J. (2009) · Trends in Microbiology · doi:10.1016/j.tim.2008.12.001 · Cited by 81
Primary prevention of HTLV-1 in Japan.
Hino, S., Katamine, S., Miyata, H., Tsuji, Y., Yamabe, T., & Miyamoto, T. (1997) · PubMed · Cited by 79
Recent advances in strategies for immunotherapy of human papillomavirus‐induced lesions
Kanodia, S., Silva, D. M. D., & Kast, W. M. (2007) · International Journal of Cancer · doi:10.1002/ijc.23252 · Cited by 69
Mucosal Immunity and Protection Against HIV/SIV Infection: Strategies and Challenges for Vaccine Design
Demberg, T., & Robert-Guroff, M. (2009) · International Reviews of Immunology · doi:10.1080/08830180802684331 · Cited by 69
Salmonella enterica Serovar Typhi Ty21a Expressing Human Papillomavirus Type 16 L1 as a Potential Live Vaccine against Cervical Cancer and Typhoid Fever
Fraillery, D., Baud, D., Pang, S., Schiller, J. T., Bobst, M., Zosso, N., Ponci, F., & Nardelli‐Haefliger, D. (2007) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00164-07 · Cited by 68
Self-citation
Transfusion‐associated hepatitis not due to viral hepatitis type A or B†
Feinstone, S. M., Kapikian, A. Z., Purcell, R. H., Alter, H. J., Holland, P. V., & Zuckerman, R. B. A. J. (2001) · Reviews in Medical Virology · doi:10.1002/rmv.304 · Cited by 57
The current state of introduction of HPV vaccination into national immunisation schedules in Europe: Results of the VENICE 2008 survey
Lévy-Bruhl, D., Bousquet, V., King, L. A., O’Flanagan, D., Bacci, S., Lopalco, P. L., & Salmaso, S. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.07.023 · Cited by 51
Tumor immunity against adult T‐cell leukemia
Kannagi, M., Harashima, N., Kurihara, K., Ohashi, T., Utsunomiya, A., Tanosaki, R., Masuda, M., Tomonaga, M., & Okamura, J. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2005.00050.x · Cited by 47
Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma
Cantarella, G., Liniger, M., Zúñiga, A., Schiller, J. T., Billeter, M., Naim, H. Y., & Glueck, R. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.061 · Cited by 46
Self-citation
Targeted Therapy for Kaposi Sarcoma
Sullivan, R. J., Pantanowitz, L., & Dezube, B. J. (2009) · BioDrugs · doi:10.2165/00063030-200923020-00001 · Cited by 43
Standardized and Highly Efficient Expansion of Epstein-Barr Virus-Specific CD4 + T Cells by Using Virus-Like Particles
Adhikary, D., Behrends, U., Feederle, R., Delecluse, H., & Mautner, J. (2008) · Journal of Virology · doi:10.1128/jvi.02227-07 · Cited by 39
PASSIVE IMMUNIZATION AGAINST HEPATITIS B: A REVIEW OF RECENT STUDIES AND COMMENT ON CURRENT ASPECTS OF CONTROL
Maynard, J. E. (1978) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112520 · Cited by 32
Induction of Protective Immunity against Murine Gammaherpesvirus 68 Infection in the Absence of Viral Latency
Jia, Q., Freeman, M. L., Yager, E. J., McHardy, I. H., Tong, L. M., Martinez-Guzman, D., Rickabaugh, T. M., Hwang, S., Blackman, M. A., Sun, R., et al. (2009) · Journal of Virology · doi:10.1128/jvi.01543-09 · Cited by 30
Epstein-Barr virus vaccine development: a lytic and latent protein cocktail
Timothy, D. L. (2008) · Frontiers in bioscience · doi:10.2741/3126 · Cited by 29
Comparative pathobiology of Kaposi sarcoma-associated herpesvirus and related primate rhadinoviruses.
Westmoreland, S. V., & Mansfield, K. G. (2008) · PubMed · Cited by 27
Advances in HTLV-1 Peptide Vaccines and Therapeutics
Lynch, M., & Kaumaya, P. T. P. (2006) · Current Protein and Peptide Science · doi:10.2174/138920306776359803 · Cited by 23
Protective Efficacy of Multiepitope Human Leukocyte Antigen???A*0201 Restricted Cytotoxic T-Lymphocyte Peptide Construct Against Challenge With Human T-Cell Lymphotropic Virus Type 1 Tax Recombinant Vaccinia Virus
Sundaram, R., Lynch, M. P., Rawale, S. V., Dakappagari, N. K., Young, D. C., Walker, C. M., Lemonnier, F. A., Jacobson, S., & Kaumaya, P. T. P. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200411010-00001 · Cited by 20
Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus
Delecluse, H., Feederle, R., Behrends, U., & Mautner, J. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.09.001 · Cited by 14

Research works printed but not linked: 7

Hino S, 1997, Leukemia, 11, 57
37. Howley PM, Lowy DR. 2007. Pappillomaviruses. See Ref. 48, pp. 2299–354
Knipe DM, 2007, Field's Virology
51. Latirmore MD, Franchini G. 2007. Human T-cell leukemia types 1 and 2. See Ref. 48, pp. 2071–105
Mast EE, 2004, Vaccines, 205
68. Richardson AB, Kieff E. 2007. Epstein-Barr virus. See Ref. 48, pp. 2655–700
Westmoreland SV, 2008, Comp. Med., 58, 31

Sorted by citations

Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,975
Human Viral Oncogenesis: A Cancer Hallmarks Analysis
Mesri, E. A., Feitelson, M. A., & Münger, K. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.011 · Cited by 672
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 337
The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches
Pandya, P. H., Murray, M. E., Pollok, K. E., & Renbarger, J. L. (2016) · Journal of Immunology Research · doi:10.1155/2016/4273943 · Cited by 270

See all 101

Authors: Schiller, J. T., & Lowy, D. R.
Affiliations: National Cancer Institute (US)
ORCID: Schiller, John T.
Lowy, Douglas R.
Venue: Annual Review of Microbiology
Publisher: Annual Reviews
Published: 2010-10-13
Volume: 64
Issue: 1
Pages: 23-41
ISSN: 0066-4227 (ISSN-L)
1545-3251
DOI: 10.1146/annurev.micro.112408.134019
PMC: PMC6264788
OpenAlex: W2118603752
Cited by: 101
References: 85
Citations by year: 2026: 6 · 2025: 6 · 2024: 11 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 7 · 2019: 4 · 2018: 3 · 2017: 5 · 2016: 9 · 2015: 2 · 2014: 4 · 2013: 9 · 2012: 15
FWCI: 1.29
Type: journal article
Language: en
Open access: green
europepmc.org
Locations: Annual Review of Microbiology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (ZIABC010579)
Topics: Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
Keywords: viral etiology of cancer, human papillomavirus, hepatitis B virus, hepatitis C virus, Epstein-Barr virus, Kaposi's sarcoma-associated herpesvirus, virus-like particle vaccine, vaccine delivery, resource-limited settings, vaccine safety and effectiveness
MeSH terms: Herpesvirus 4, Human, Hepatitis B, Hepatitis B virus, Hepatitis C, Herpesviridae Infections, Humans, Neoplasms, Retroviridae, Viral Vaccines, Hepacivirus, Herpesvirus 8, Human, Epstein-Barr Virus Infections, Papillomaviridae, Papillomavirus Infections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Vaccines to Prevent Infections by Oncoviruses

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks